Product · #20 of 27 · multi-symptom (single active)

Equelle Menopause Multi-Symptom Relief

Tablet from Equelle, made by Bonafide / Pharmavite (Otsuka). Daily serving: 2 tablets.

Last updated · Price and ratings checked Nov 19, 2026

In short: Equelle Menopause Multi-Symptom Relief scores 47.4/100 in our ranking (#20 of 27). It costs $1.40 a day at the regular price. Evidence: S-equol 10 mg; own trials, one without placebo, sponsor-funded; best ingredient grade C (S-equol). No NSF registry listing was confirmed.

Pros

  • Has its own published product trials (2 in our library); see who funded them below.
  • Evidence: S-equol 10 mg; own trials, one without placebo, sponsor-funded.

Cons

  • No NSF registry listing confirmed.

Flags

Watchdog complaint

Score breakdown

Evidence
25/40
NSF-verified testing
4/20
Value ($/day)
10.7/20
Ingredients
4/10
Amazon rating
3.7/10

How we score

Full label: what's in it

Supplement Facts actives per daily serving (2 tablets). Source: label or official page, checked Nov 19, 2026.
Ingredient (as labeled)Per dayEvidence page
S-equol (from fermented soy germ)10 mgS-equol C
Calcium240 mgVitamin D & calcium B

Label read from the official product image.

Evidence

Our evidence score: 25/40, because: S-equol 10 mg; own trials, one without placebo, sponsor-funded.

Product-level research: Equelle site also cites unpublished 'Data on File 1811 Study Report'; sleep claim footnoted as 'significant vs baseline and not placebo'. Evidence grade for the branded product: C C.

Ingredient evidence

  • S-equol C (10 mg here)
    S-equol is a soy-derived compound (the active in Equelle) studied for occasional hot flashes and muscle aches associated with menopause*. Results are mixed, and the key trials were sponsored by companies behind the ingredient or product. The Menopause Society 2023: Not recommended (Level II) – mixed evidence.
  • Vitamin D & calcium B (240 mg here)
    Calcium and vitamin D support bone health*. Large trials, including the Women's Health Initiative, show a small effect on bone density, and effects on fractures are mixed. The Menopause Society 2023: Not part of VMS statement.

Studies

Trials of this product

  • A pilot study on the effects of S-equol compared to soy isoflavones on menopausal hot flash frequency.

    Jenks BH, Iwashita S, Nakagawa Y et al. · J Womens Health (Larchmt) 2012 · S-equol

    The only US hot-flash trial of S-equol compared different doses with soy isoflavones, with no placebo group. All groups improved similarly; higher doses did slightly better. It was run by Pharmavite, which makes Equelle.

    Who
    102 US postmenopausal women
    Dose
    S-equol 10, 20 or 40 mg/day vs soy isoflavones (no placebo)
    Duration
    8 weeks
    Result
    Similar hot-flash reductions at week 8; 40 mg beat isoflavones on cumulative analysis; 10–20 mg better for muscle/joint pain.
    Funding
    Pharmavite LLC (Equelle maker) – lead author employee. Industry-linked

    PubMed · Full text (DOI)

  • A natural S-equol supplement alleviates hot flushes and other menopausal symptoms in equol nonproducing postmenopausal Japanese women.

    Aso T, Uchiyama S, Matsumura Y et al. · J Womens Health (Larchmt) 2012 · S-equol

    160 Japanese women who could not make equol themselves took 10 mg S-equol or placebo for 12 weeks. Hot flashes fell about 59% vs 35% on placebo. The ingredient's maker ran the research, and Japanese women tend to have milder hot flashes than US women.

    Who
    160 Japanese equol non-producers (126 completed)
    Dose
    natural S-equol 10 mg/day
    Duration
    12 weeks
    Result
    Hot flushes -58.7% vs -34.5% placebo (P=.009); less neck/shoulder stiffness.
    Funding
    Otsuka Pharmaceutical (developer of the S-equol ingredient used in Equelle). Industry-linked

    PubMed · Full text (DOI)

Studies on its ingredients (1)
  • Equol Decreases Hot Flashes in Postmenopausal Women: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

    Daily JW, Ko BS, Ryuk J et al. · J Med Food 2019 · S-equol

    An analysis of 6 trials found S-equol lowered hot-flash scores overall, but 2 of the 5 pooled trials found no benefit and most trials were small.

    Who
    6 RCTs, 779 women
    Dose
    S-equol or isoflavones in equol producers
    Duration
    various
    Result
    Pooled benefit on hot-flash scores; 3 of 5 trials positive, 2 null.
    Funding
    Academic (Korea); not stated as industry funded. Independent / academic

    PubMed · Full text (DOI)

The Menopause Society's 2023 statement is in the study library.

Price

Regular one-time price$42.00 (60 units, 30 days at label dose)
Cost per day$1.40
Subscription30-day $39.90/mo; 90-day $111 ($37/mo)
Price notesAmazon B0FTTCLPB2 60 ct $44.99
In stock when checkedYes
CheckedNov 19, 2026

Ratings

Amazon: ★ 4.2 from 314 ratings on Amazon (checked Nov 19, 2026)

Brand site: ★ 4.2, 2,717 reviews on equelle.com (checked Nov 19, 2026). Brand-site reviews are moderated by the brand.

Star ratings reflect buyer satisfaction, not clinical effect.

Certifications and claims

Verified in a public registry

  • No registry listing found.

Claims made by the brand

  • “hormone-free* (contains plant isoflavone metabolite)” Brand claim
  • “clinically studied” Brand claim

Registry check: NSF/ANSI 173: not found

Who's behind it

BrandEquelle
Owner / companyBonafide Health, LLC dba Equelle (Harrison, NY) – Pharmavite LLC.
FoundersNot stated on the pages we read.
Where it's madenot stated.
Medical advisors namedNone named on the pages we read.
Sourceequelle.com

Flags & safety

Legal, regulatory and quality flags

  • TINA.org complaint to FTC & FDA (Oct 2024) alleging deceptive marketing of Equelle (Pharmavite). truthinadvertising.org

Ingredient safety notes

  • S-equol: Soy-derived; avoid with soy allergy. Breast-cancer-history safety not established for concentrated isoflavone products. US trial lacked placebo; most data in Japanese women.
  • Vitamin D & calcium: Kidney stones increased (WHI HR 1.17). WHI long-term follow-up: CVD mortality HR 1.06, cancer mortality HR 0.93.

Sources

Talk to a clinician first

The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).

If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.